CA2596966A1 — Implantable osmotic device for continuous delivery of suspension formulations
Assigned to Intarcia Therapeutics Inc · Expires 2006-08-10 · 20y expired
What this patent protects
An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 ~g/day to maintain and achieve therapeutic blood or plasma levels of…
USPTO Abstract
An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 ~g/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.